
Today’s approval is an important public health milestone in acute pain management.
Acting director of the Food and Drug Administration’s Center for Drug Evaluation and Research, Dr. Jacqueline Corrigan-Curay, in a statement on Thursday following the FDA’s approval of Journavx, a non-opioid painkiller that treats moderate to severe acute pain.
Why It Matters: The FDA’s announcement marks the first new type of pain medication approved in 25 years, which has been positioned as an alternative to opioids. According to a study conducted by the company that developed the drug, about 80 million Americans fill prescriptions each year to treat moderate to severe pain; in about about half of those cases, medical professionals prescribe opioid medication, which can have higher risk for addiction. With Journavx now on the market, medical professionals have more non-opioid prescription options.
- Studies have not yet indicated whether the drug can be safely and effectively used by children.
- It may not be effective for all types of pain, as one study indicated it made little impact for those experiencing chronic pain.
- Since President Donald Trump’s inauguration, all federal health agencies have been instructed to pause external communications. The FDA’s Journavx announcement is the first communication to the public since the new administration took office, as announcements are made on a “case-by-case basis” as health agencies undergo a review.
Read More: The FDA announcement
FDA approves new, non-opioid painkiller Journavx (The Washington Post)
Image Credit: everythingpossible / Adobe Stock
by Emily Hooker, based in Texas




